Funding
← Back to your selection

Duquesne Family Office

Activity from announced rounds

Activity in this selectionOct 21, 2026 · Jul 24, 2026

Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.

Recorded funding activity

Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.

Sources
Rounds participated in
4
Confirmed lead rounds
0
2 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$910M
4 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series A1

By primary sector

Biotech2
Hardware1
Healthtech1

By country

United States4

Rounds

4 in this selection
Precision Neuroscience

Develops a brain-computer interface intended to help people with paralysis operate digital devices.

$250MSeries D
Participant
Fab2

Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication.

$500MSeries A
Participant
Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C
Role not disclosed